N/A N=142 Optimal Duration of Indwelling Urinary Catheter Following Pelvic Surgery
Urinary Retention
Primary: Number of Participants With Acute Urinary Retention — 6; 7 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=120 Does Tranexamic Acid Decrease Blood Loss in Pediatric Idiopathic Scoliosis Surgery?
Adolescent Idiopathic Scoliosis
Primary: Perioperative Blood Loss — 1031; 836 mL — p=<0.001
Phase 1 N=32 Bioequivalence Trial of Concor AM® vs Bisoprolol and Amlodipine in Chinese Participants
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t)…
Phase 4 N=21 Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
Retinal Vein Occlusion · Age Related Macular Degeneration
Primary: Mean Change From Baseline in Best Correct Visual Acuity (BCVA) — 9.55 Letters
Phase 2 N=86 A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults
Dengue
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms — 7; 2; 4; 5 Participants
N/A N=27 Reducing Sedentary Behavior to Decrease Low Back Pain: Stand Back Study
Chronic Low Back Pain
Primary: Low Back Pain Disability — 12.1; 19.6 Oswestry Disability %
N/A N=126 Clinical Evaluation of Percutaneous Implantation of the Medtronic CoreValve Aortic Valve Prosthesis (18Fr-Study)
Aortic Valve Stenosis
Primary: Composite Major Adverse Event (MAE) Free Rate — 54.2; 48.1; 51.6 Percentage of subjects
Phase 2 N=22 Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors
Neuroendocrine Tumors
Primary: Efficacy of Combination Sorafenib Plus Metronomic Cyclophosphamide in Advanced, Progressive NET, as Measured by the Objective Response Rate (ORR). — 1 Participants
Phase 1 N=6 Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Dense Deposit Disease · Membranoproliferative Glomerulonephritis
Primary: Number of Patients With Change in Proteinuria or Serum Creatinine Over Treatment Period — 5 Participants
Phase 1 N=36 A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
Healthy
Primary: Cmax of Narlaprevir — 2130.2742; 2172.233; 2946.131; 2880.612 ng/ml
N/A N=9 Deep Brain Stimulation in Patients With Dystonia
Dystonia
Primary: The Toronto Western Spasmodic Rating Scale (TWSTRS) Movement Scores Measured Before DBS Surgery (Baseline) and at 12 Months — 33.5 TWSTRS total score change
N/A N=108 ExAblate UF V2 System for the Treatment of Symptomatic Uterine Fibroids
Uterine Fibroids
Primary: Percentage of Participants With Leg Pain or Lower Extremity Neuropathy Persisting or Occuring Greater Than 10 Days Following Treatment — 0 Percentage of participants
N/A N=99 Adenotonsillectomy Postoperative Parental Teaching Tool
Tonsillectomy
Primary: Difference in Answers to Pre & Post Teaching Questionnaires — -1; 0; 0 difference in testing scores
Phase 3 N=16 Randomized Study Comparing Local Tumor Control After Post-Operative Single-Fraction or Hypofractionated Stereotactic Radiosurgery in the Treatment of Spinal Metastases
Spinal Metastases
Primary: Local Tumor Control Using MRI or CT
N/A N=55 Pain and Function After Orthopedic Surgery
Chronic Pain
Primary: Self-reported Pain Intensity — 3 units on a scale